The 2023 Bethesda System for Reporting Thyroid Cytopathology
Abstract
Since the publication of the first edition in 2010, The Bethesda System for Reporting Thyroid Cytopathology has allowed cytopathologists to use a standardized, category-based reporting system for thyroid fine needle aspirations. The third edition builds on the success of the 2 earlier editions and offers several key updates. The most important is the assignment of a single name for each of the 6 diagnostic categories: (i) nondiagnostic; (ii) benign; (iii) atypia of undetermined significance; (iv) follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. Each of the categories has an implied risk of malignancy (ROM), which has been updated and refined based on data reported after the second edition. The third edition offers an average ROM for each category, in addition to the expected range of cancer risk. The atypia of undetermined significance subcategorization is simplified into 2 subgroups based on the implied ROM and molecular profiling. A discussion of pediatric thyroid disease has been added, and pediatric ROMs and management algorithms are discussed in the relevant sections. Nomenclature has been updated to align with the 2022 World Health Organization Classification of Thyroid Neoplasms. Two new chapters have been added: one that addresses the significant and expanded use of molecular and ancillary testing in thyroid cytopathology, and another that summarizes clinical perspectives and imaging findings in thyroid disease.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009;19:1159–1165.
2. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. J Am Soc Cytopathol 2017;6:217–222.
3. Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology Definitions, Criteria and Explanatory Notes. Springer US: Boston, MA, USA; 2010.
4. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017;27:1341–1346.
5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–133.
6. Carty SE, Ohori NP, Hilko DA, et al. The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV nodules). Ann Surg 2020;272:621–627.
7. Ali SZ, VanderLaan PA. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes, 3rd ed. Springer: New York, NY, USA; 2023.
8. WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine Tumours, Vol. 8. 5th ed. International Agency for Research on Cancer: Lyon, France; 2022.
9. Cherella CE, Angell TE, Richman DM, et al. Differences in thyroid nodule cytology and malignancy risk between children and adults. Thyroid 2019;29:1097–1104.
10. Vuong HG, Chung DGB, Ngo LM, et al. The use of the Bethesda system for reporting thyroid cytopathology in pediatric thyroid nodules: A meta-analysis. Thyroid 2021;31:1203–1211.
11. Renshaw AA. Histologic follow-up of nondiagnostic thyroid fine needle aspirations: Implications for adequacy criteria. Diagn Cytopathol 2012;40:E13—E15.
12. Vivero M, Renshaw AA, Krane JF. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. Cancer Cytopathol 2017;125: 534–543.
13. Ferreira MA, Gerhard R, Schmitt F. Analysis of nondiagnostic results in a large series of thyroid fine-needle aspiration cytology performed over 9 years in a single center. Acta Cytol 2014;58:229–234.
14. Souteiro P, Polónia A, Eloy C. Repeating thyroid fine-needle aspiration before 3 months may render increased nondiagnostic results. Clin Endocrinol 2019;91:899–900.
15. Singh RS, Wang HH. Timing of repeat thyroid fine needle aspiration in the management of thyroid nodules. Acta Cytol 2011;55:544–548.
16. Lee HY, Baek JH, Yoo H, et al. Repeat fine-needle aspiration biopsy within a short interval does not increase the atypical cytologic results for thyroid nodules with previously nondiagnostic results. Acta Cytol 2014;58:330–334.
17. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022;33:27–63.
18. Olson MT, Clark DP, Erozan YS, et al. Spectrum of risk of malignancy in subcategories of ‘atypia of undetermined significance.’ Acta Cytol 2011;55:518–525.
19. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol 2011;136:572–577.
20. Cherella CE, Hollowell ML, Smith JR, et al. Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules. Cancer Cytopathol 2022;130:330–335.
21. Glass RE, Levy JJ, Motanagh SA, et al. Atypia of undetermined significance in thyroid cytology: Nuclear atypia and architectural atypia are associated with different molecular alterations and risks of malignancy. Cancer Cytopathol 2021;129:966–972.
22. Krane JF, Alexander EK, Cibas ES, et al. Coming to terms with NIFTP: A provisional approach for cytologists. Cancer Cytopathol 2016;124:767–772.
23. Strickland KC, Howitt BE, Barletta JA, et al. Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules. Cancer Cytopathol 2018;126: 86–93.
Information & Authors
Information
Published In

Copyright
Copyright 2023, Mary Ann Liebert, Inc., publishers.
History
Published online: 13 September 2023
Published in print: September 2023
Published ahead of print: 8 July 2023
Topics
Authors
Authors' Contributions
S.Z.A.: Visualization, writing-original draft, writing-reviewing and editing. Z.W.B.: Data curation, writing-reviewing and editing. B.C.-P.: Writing-reviewing and editing. F.C.S.: Writing-reviewing and editing. P.A.V.: Visualization, writing- reviewing and editing.
Author Disclosure Statement
The authors made no disclosures.
Funding Information
No specific funding was disclosed.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.